JonathanMichaelGerberMD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Director of the UMass Cancer Center Chief of Hematology & Oncology Eleanor Eustis Farrington Chair in Cancer Research

Dr. Gerber is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
55 Lake Ave N
Worcester, MA 01655
Phone+1 774-442-3903

Fax+1 774-442-6715

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
Johns Hopkins UniversityResidency, Internal Medicine, 2002 - 2005
Johns Hopkins UniversityResidency, Orthopaedic Surgery, 1999 - 2001
Johns Hopkins University School of MedicineClass of 1999

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH Start of enrollment: 2021 Feb 28
Recruiting
Phase 1
Roles: Contact, Principal Investigator

PubMed

17 citations
Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study.
Xianming Zhu, Kelly A Gebo, Alison G Abraham, Feben Habtehyimer, Eshan U Patel
The Lancet. Microbe. 2023-09-01
5 citations
Establishment and functional characterization of a murine primary Sertoli cell line deficient of connexin43
Jonathan Gerber, Kristina Rode, Nina Hambruch, Marion Langeheine, Nadine Schnepel
Cell and Tissue Research. 2020-04-23
35 citations
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern.
Maggie Li, Evan J Beck, Oliver Laeyendecker, Yolanda Eby, Aaron A R Tobian
Blood Advances. 2022-06-28

Abstracts/Posters

Patient Reported Financial Toxicity in Myeloproliferative Neoplasms
Jonathan M. Gerber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Relationship of minimal residual disease (MRD) in acute lymphocytic leukemia (ALL) and putative leukemia stem cells (LSCs).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

UMass Chan Researcher Explains Convalescent Plasma’s Potential as COVID-19 TreatmentFebruary 16th, 2022
Early Use of Convalescent Plasma Treatment for COVID-19 Helps Avoid HospitalizationDecember 23rd, 2021
‘We Can Deal with This Virus': In Partnership with Johns Hopkins, UMass Medical School in Worcester Needs Volunteers to Test Early Diagnosis Coronavirus TreatmentSeptember 21st, 2020
Join now to see all